Aurobindo Pharma reported robust cash flows and is evaluating options to return value to shareholders, including a potential share buyback program or dividend distribution. The company generated Rs 2,434.50 crore from operating activities, a 2% increase year-over-year. Despite increased investing activities and decreased financing cash flows, Aurobindo maintains a strong operational cash generation, investing Rs 3,561.50 crore in capital expenditure. The company's board is actively considering shareholder return options, signaling confidence in its financial health.
Aurobindo Pharma Sets Sights on US Biosimilars Market with FY26 FDA Submission Plan
Aurobindo Pharma plans to enter the US biosimilars market, targeting its first FDA submission in fiscal year 2026. The company is developing eight biosimilar candidates for a market projected to exceed $50 billion by 2030. This strategic move aims to diversify Aurobindo's portfolio, drive revenue growth, and strengthen its global position. However, the company faces regulatory hurdles, increasing competition, and manufacturing complexities in this venture.
Aurobindo Pharma's Q4 results show a 10.65% increase in revenue to ₹8,382.00 crore, but net profit remained nearly flat at ₹903.50 crore, missing analysts' expectations. EBITDA improved by 7% to ₹1,792.00 crore, while the EBITDA margin slightly decreased to 21.40%. The company demonstrated strong sales performance but faced pressure on profit margins.
20May 25
USFDA Flags Quality Control Concerns at Aurobindo Pharma Facility
Aurobindo Pharma, a major Indian pharmaceutical company, is under USFDA scrutiny due to quality control issues at one of its facilities. The FDA inspection revealed inadequate documentation of quality control procedures and incomplete investigations of unexplained discrepancies. These findings could impact Aurobindo's regulatory compliance, necessitate quality assurance improvements, and potentially require significant remediation efforts.
14May 25
Aurobindo Pharma's Subsidiary Secures UK Approval for Biosimilar Zefylti
Aurobindo Pharma's subsidiary, Curateq Biologics, has received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its biosimilar product, Zefylti. This approval marks a significant milestone in Aurobindo's international expansion and strengthens its position in the biosimilar market. The approval is expected to facilitate market expansion in the UK, diversify Aurobindo's product portfolio, potentially increase revenue, and enhance its competitive position in the global biosimilar landscape.
30Apr 25
Aurobindo Pharma Faces ₹70.59 Million Tax Setback as Appeal Rejected
Aurobindo Pharma's appeal against a GST tax demand has been rejected by the Appellate Authority. The company now faces a total disputed amount of ₹70.59 million, including ₹37.45 million for Input Tax Credit reversal, ₹29.39 million in interest, and a ₹3.75 million penalty. The tax authorities allege excess Input Tax Credit claims and improper ITC claims from non-compliant suppliers. Aurobindo Pharma plans to appeal to the GST Appellate Tribunal and states the order has no material impact on its financials or operations.
29Apr 25
Aurobindo Pharma's Kakinada Facility Faces Temporary Shutdown After Fire Incident
Aurobindo Pharma reported a fire incident at its Kakinada facility on April 27, 2025, causing a temporary production halt for 20-25 days. The fire, caused by coal self-ignition, damaged ancillary equipment but left core manufacturing infrastructure intact. No injuries were reported. The facility is fully insured, and the company expects no material financial impact. Operations will resume after equipment replacement and safety protocol review.
28Apr 25
Aurobindo Pharma: Fire Incident and Positive CHMP Opinion for Biosimilar
Aurobindo Pharma experienced a fire at its penicillin-G facility in Kakinada SEZ, causing a 20-25 day operational pause. The company expects no material financial impact. On a positive note, Aurobindo's subsidiary, Curateq Biologics, received a favorable CHMP opinion for its trastuzumab biosimilar, Dazublys, for treating certain breast and gastric cancers in the EU. This marks a significant step towards potential EU market authorization and expansion in the biosimilars market.
26Apr 25
Aurobindo Pharma's Subsidiary Receives Positive CHMP Opinion for Trastuzumab Biosimilar
CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has received a positive opinion from the CHMP recommending marketing authorization for Dazublys®, a trastuzumab biosimilar. The drug is intended for treating HER2-positive metastatic and early breast cancers. This marks the company's third biosimilar to receive CHMP endorsement. European Commission approval is expected in July, potentially making Dazublys® available across EU member states. Aurobindo Pharma aims to launch at least 10 biosimilars by 2030 in oncology and immunology therapy segments.
23Apr 25
Aurobindo Pharma's Subsidiary Secures FDA Nod for Lucrative Cancer Drug, Stock Rises
Aurobindo Pharma's subsidiary, Eugia Pharma Specialities Limited, has received FDA approval to manufacture and market Dasatinib tablets for leukemia treatment. The approval covers various strengths and is bioequivalent to Bristol-Myers Squibb's Sprycel Tablets. The product has an estimated market size of US$ 1.80 billion. Aurobindo plans to launch the tablets in Q1FY26. This marks Eugia Pharma's 181st ANDA approval, boosting Aurobindo's presence in the oncology market.
15Apr 25
Aurobindo Pharma Secures FDA Approval for Rivaroxaban Tablets, Tapping into $8.5 Billion US Market
Aurobindo Pharma has received FDA approval for its Rivaroxaban Tablets USP 2.5mg strength, with tentative approval for other strengths. This anticoagulant medication represents an $8.50 billion market opportunity in the US. The approval enhances Aurobindo's portfolio, increases revenue potential, and provides a competitive edge in the US pharmaceutical market.
13Apr 25
Aurobindo Pharma Secures FDA Approval for Generic Rivaroxaban, Targeting $8.5B Market
Aurobindo Pharma received FDA approval for generic Rivaroxaban 2.5mg tablets on April 12, 2025. The product is bioequivalent to Janssen's XARELTO®. Aurobindo plans to launch in Q1 FY2025-26, targeting a $447 million market. The company also has tentative approvals for 10mg, 15mg, and 20mg strengths, with a total market potential of $8.50 billion. This marks Aurobindo's 540th ANDA approval, reinforcing its position in the U.S. generic drug market.
11Apr 25
Aurobindo Pharma's US Subsidiary Receives 11 FDA Observations at Raleigh Facility
Aurobindo Pharma's US subsidiary, Aurolife Pharma LLC, received 11 procedural observations from the FDA following an inspection at its Raleigh, North Carolina facility. The inspection took place from March 24 to April 10, 2025. The company stated that these observations are not expected to significantly impact plant operations. Aurobindo Pharma plans to submit a comprehensive response within the stipulated timeline and implement corrective actions. The company maintains that there will be no material impact on current business operations or existing supplies from the Raleigh facility.
Aurobindo Pharma's CuraTeQ Biologics Achieves Milestone in Denosumab Biosimilar Development
CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has successfully completed a Phase 1 study for BP16, a biosimilar to denosumab (Prolia® and Xgeva®). The study involving 204 healthy volunteers showed BP16's pharmacokinetic profile to be nearly identical to the reference products, meeting key bioequivalence parameters. The company is now progressing with a Phase 3 study in the EU, focusing on postmenopausal osteoporosis, with anticipated completion by May/June 2025. CuraTeQ aims to submit a Marketing Authorization application to CHMP/EMA in Q3 of the fiscal year.
19Mar 25
Aurobindo Pharma Subsidiary Receives VAI Classification from US FDA
Aurobindo Pharma's subsidiary, Apitoria Pharma Private Limited, received a 'Voluntary Action Indicated' (VAI) classification from the FDA for its Unit-V API manufacturing facility in Telangana after an inspection from December 9-17, 2024. The VAI status suggests minor issues that don't require regulatory action. Separately, shareholders approved the re-appointment of Mr. Santanu Mukherjee as an Independent Director for a 5-year term with 91.02% votes in favor.
Aurobindo Pharma Limited has officially terminated its license agreement with Hilleman Laboratories Singapore, potentially signaling a shift in its research and development strategy. The termination could impact the company's product pipeline and future collaborations. Separately, Aurobindo Pharma has scheduled an investor meeting for March 12, 2025, in Hyderabad, arranged by Macquarie.
03Mar 25
Aurobindo Pharma Expands Biotech Presence with 80% Stake Acquisition in Tergene Biotech
Aurobindo Pharma has completed the acquisition of an 80% stake in Tergene Biotech, a step-down subsidiary and joint venture company. This strategic move aims to strengthen Aurobindo's position in the biotech sector, potentially expanding its capabilities, diversifying its portfolio, and enhancing its market presence in biotechnology.
28Feb 25
Aurobindo Pharma Completes Acquisition of 80% Stake in Tergene Biotech
Aurobindo Pharma has completed the acquisition of an 80% stake in Tergene Biotech Limited for Rs. 107.6 million, transforming it from a step-down subsidiary into a direct subsidiary. The transaction, approved on February 6, 2025, and completed on February 28, 2025, is expected to strengthen Aurobindo's position in the biotech sector, potentially enhancing its capabilities in biotechnology research, vaccine development, and expanding its product pipeline.
20Feb 25
Aurobindo Pharma's US Subsidiary Faces FDA Scrutiny: New Jersey Warehouse Receives 'Official Action Indicated' Classification
Aurobindo Pharma's US subsidiary warehouse in New Jersey has been classified as 'Official Action Indicated' (OAI) by the US FDA following an inspection from May 13-15, 2024. The inspection, focused on Drug Supply Chain Security Act compliance, resulted in five observations. Despite this, the company doesn't foresee any immediate business impact and commits to working closely with the FDA to enhance compliance measures.